Advertisement
Home Tags Cancer: Breast

Tag: Cancer: Breast

Ultrasound and mammography appear equally likely to detect breast cancer

Breast CA Detection Comparable for Ultrasound, Mammography

0
But ultrasound has more false positives, researchers find
BRCA1/2 mutation carriers have increased risk of contralateral breast cancer (CBC)

Early First Cancer in BRCA1/2 Ups Risk in Opposite Breast

0
For mutation carriers, age at diagnosis of first cancer predicts contralateral breast cancer risk
For premenopausal women with breast cancer

Adding Triptorelin to Breast CA Chemo May Up Ovarian Recovery

0
Findings for premenopausal women with hormone-positive or hormone-negative breast cancer
Periodontal disease is associated with increased risk of breast cancer among postmenopausal women

Periodontal Disease Linked to Increased Breast Cancer Risk

0
Increased risk of postmenopausal breast cancer, especially for smokers who quit within last 20 years
Histopathologic patterns and biomarkers for invasive breast cancer correlate with differences in findings on sonographic imaging

Ultrasound Findings in Invasive Breast CA Link to Histopathology

0
Histopathologic patterns, breast cancer biomarkers determine differences in findings on imaging
Neoadjuvant chemotherapy is less likely to benefit black women with breast cancer than those in other racial and ethnic groups

Early Chemo Less Likely to Help Black Breast Cancer Patients

0
More research needed to explain why outcomes differ among black, Hispanic, and Asian women

San Antonio Breast Cancer Symposium, Dec. 8-12

0
The 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium The annual meeting of the San Antonio Breast Cancer Symposium was held from Dec....
Vistogard (uridine triacetate) has been approved by the U.S. Food and Drug Administration to treat an overdose of the chemotherapy drugs fluorouracil and capecitabine

FDA Approves Vistogard to Treat Chemotherapy Overdose

0
For overdose of the chemo drugs fluorouracil and capecitabine
Pharmaceutical industry-sponsored studies are more likely to report favorable estimates in cost-effectiveness analysis of drugs used in breast cancer treatment

Industry-Led Oncology Trials May Inflate Cost-Effectiveness

0
Breast cancer cost-effectiveness analyses show favorable estimates with industry funding
Postmenopausal women with hormone receptor-positive ductal carcinoma in situ have similar recurrence rates of disease whether they take tamoxifen or the aromatase inhibitor anastrozole after surgery

SABCS: Tamoxifen, Anastrozole Both Prevent Recurrence in DCIS

0
However, side effects differ for the two medications